share_log

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K: HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

8-K:HeartSciences提供最新業務並報告2025財年第一季度財務業績
美股SEC公告 ·  09/12 16:20

Moomoo AI 已提取核心訊息

On September 12, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, reported its financial and operational results for the first quarter of fiscal year 2025, which ended on July 31, 2024. The company, which specializes in AI-powered medical technology for heart disease detection, highlighted the progress of its MyoVista wavECGTM device and MyoVista InsightsTM cloud platform. HeartSciences announced a cash and cash equivalents balance of $4.3 million and shareholder’s equity of $5.9 million. Post-quarter, the company secured $1.9 million in non-dilutive financing and extended a $500,000 loan note. The MyoVista Insights Platform is expected to be completed by the end of 2024, with FDA submission targeted for the second half of 2025. The FDA 510(k) submission for the MyoVista wavECGTM device is on track for early 2025. The company also showcased its technology at the United Nations General Assembly Digital Health Symposium and expanded its intellectual property portfolio. Despite these advancements, HeartSciences reported no revenues for Q1 FY2025. The complete financial results have been filed with the U.S. Securities and Exchange Commission.
On September 12, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, reported its financial and operational results for the first quarter of fiscal year 2025, which ended on July 31, 2024. The company, which specializes in AI-powered medical technology for heart disease detection, highlighted the progress of its MyoVista wavECGTM device and MyoVista InsightsTM cloud platform. HeartSciences announced a cash and cash equivalents balance of $4.3 million and shareholder’s equity of $5.9 million. Post-quarter, the company secured $1.9 million in non-dilutive financing and extended a $500,000 loan note. The MyoVista Insights Platform is expected to be completed by the end of 2024, with FDA submission targeted for the second half of 2025. The FDA 510(k) submission for the MyoVista wavECGTM device is on track for early 2025. The company also showcased its technology at the United Nations General Assembly Digital Health Symposium and expanded its intellectual property portfolio. Despite these advancements, HeartSciences reported no revenues for Q1 FY2025. The complete financial results have been filed with the U.S. Securities and Exchange Commission.
2024年9月12日,Heart Test Laboratories, Inc.,即HeartSciences,發佈了其2025財年第一季度的財務和運營結果,截至2024年7月31日。該公司專注於基於人工智能的醫療技術,用於心臟疾病檢測,並強調了其MyoVista wavECGTm設備和MyoVista InsightsTm雲平台的進展。HeartSciences宣佈現金及現金等價物餘額爲430萬美元,股東權益爲590萬美元。季度後,該公司獲得了190萬美元的非稀釋融資,並延長了50萬元的貸款票據。預計MyoVista Insights平台將於2024年底完成,FDA的提交目標爲2025年下半...展開全部
2024年9月12日,Heart Test Laboratories, Inc.,即HeartSciences,發佈了其2025財年第一季度的財務和運營結果,截至2024年7月31日。該公司專注於基於人工智能的醫療技術,用於心臟疾病檢測,並強調了其MyoVista wavECGTm設備和MyoVista InsightsTm雲平台的進展。HeartSciences宣佈現金及現金等價物餘額爲430萬美元,股東權益爲590萬美元。季度後,該公司獲得了190萬美元的非稀釋融資,並延長了50萬元的貸款票據。預計MyoVista Insights平台將於2024年底完成,FDA的提交目標爲2025年下半年。MyoVista wavECGTm設備的FDA 510(k)提交計劃於2025年初完成。該公司還在聯合國大會數字健康研討會上展示了其技術,並擴展了其知識產權組合。儘管取得了這些進展,HeartSciences報告稱2025財年第一季度無收入。完整的財務結果已向美國證券交易委員會提交。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息